Volume 17 Issue 3 LipidSpin Articles | National Lipid Association Online

ALAN S. BROWN, MD, FNLA	NLA Awareness & Leadership Development – A Year in Review President of the National Lipid Association for the past year. Thank you to this wonderful organization for allowing me to achieve many of the goals we set for the 2018-2019 year. As you will read below, the theme for my Presidency continues to be leadership development and organizational awareness – two goals I know Antonio Gotto, Jr. MD, DPhil, FNLA will continue to foster during his term. I am thrilled to share the work of the... more
PAMELA B. MORRIS, MD, FACC, FAHA, FASPC, FNLA	From the SELA President: Seeing the Whole Elephant: The Argument for Collaboration in Lipid Disorder Treatment As lipid specialists, members of the National Lipid Association (NLA) specialize in the care of patients with complex lipid disorders and most experts utilize a collaborative, multidisciplinary team approach for comprehensive lifestyle and pharmacological management. Given the increasingly limited time clinicians are allotted to spend with patients during a routine clinic visit in today’s high-volume medical practices, it can be... more
DANIEL E. SOFFER MD, FNLA	Editor's Corner: Preventive Cardiologist? Lipid Specialist? Who’s On First? Who am I? This is the essential existential question that everyone needs to ask at some point in life. At the National Lipid Association (NLA), this is a question that we will be asking ourselves over the next few years as our field redefines itself. Is it enough that we are Lipid Specialists or do we practice Preventive Cardiology or are we Cardiometabolic Health Specialists? This is a question that every member and the NLA... more
LEAH JOHN, MD, MBA JAN BASILE, MD	Clinical Feature: Hitting Moving Targets: Identification and Management of HypertensiHitting Moving Targets: Identification and Management of Hypertension for CV Risk Reductionon for CV Risk Reduction Background In the United States, hypertension accounts for more cardiovascular disease (CVD) deaths than any other modifiable CVD risk factor and is second only to cigarette smoking as a preventable cause of death. In 2010, high blood pressure (BP) was the leading cause of death and disability worldwide. Although hypertension remains the most common modifiable risk factor for CVD, a large portion of the population still has BP that remains uncontrolled. New guideline... more
GREGORY S. POKRYWKA, MD, FACP, FASPC, NCMP, FNLA DHARMESH PATEL, MD, FACC, MBBS (London), FACP, FNLA, FASPC	Lipid Luminations: Deep Dive Into FOURIER Subgroup Analyses The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial was a randomized trial in 27,564 patients with stable atherosclerotic cardiovascular disease (ASCVD), evaluating evolocumab vs placebo added to statin therapy.(1) The hazard ratio for reduction of the primary endpoint (composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary endpoint... more